BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 15056496)

  • 1. Nonchannel drug targets in atrial fibrillation.
    Goette A; Lendeckel U
    Pharmacol Ther; 2004 Apr; 102(1):17-36. PubMed ID: 15056496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of atrial fibrillation.
    Hersi A; Wyse DG
    Curr Probl Cardiol; 2005 Apr; 30(4):175-233. PubMed ID: 15778690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Morphological remodeling in atrial fibrillation].
    Goette A; Lendeckel U
    Herz; 2006 Apr; 31(2):101-7; quiz 142-3. PubMed ID: 16738831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Molecular biology of the heart atrium. New insights into the pathophysiology of atrial fibrillation as well as its clinical implications].
    Goette A; Lendeckel U; Klein HU
    Z Kardiol; 2004 Nov; 93(11):864-77. PubMed ID: 15568146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tracing the origins of postoperative atrial fibrillation: the concept of oxidative stress-mediated myocardial injury phenomenon.
    Elahi MM; Flatman S; Matata BM
    Eur J Cardiovasc Prev Rehabil; 2008 Dec; 15(6):735-41. PubMed ID: 19020458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug therapy for termination of atrial fibrillation and maintenance of sinus rhythm.
    Talajic M; Roy D
    Can J Cardiol; 2005 Sep; 21 Suppl B():19B-25B. PubMed ID: 16239983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Drugs for heart rate control and non-antiarrhythmic drugs in atrial fibrillation].
    Chávez LL
    Arch Cardiol Mex; 2007; 77 Suppl 2():S2-54-S2-58. PubMed ID: 17972380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atrial structural remodeling as an antiarrhythmic target.
    Burstein B; Nattel S
    J Cardiovasc Pharmacol; 2008 Jul; 52(1):4-10. PubMed ID: 18594481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Non-channel drugs to prevent atrial fibrillation].
    Fazekas T; Liszkai G
    Orv Hetil; 2005 Nov; 146(45):2287-94. PubMed ID: 16304807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation.
    Korantzopoulos P; Kolettis TM; Galaris D; Goudevenos JA
    Int J Cardiol; 2007 Feb; 115(2):135-43. PubMed ID: 16764958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacologic treatment of atrial fibrillation].
    Lelakowski J
    Pol Merkur Lekarski; 2008 Oct; 25(148):303-8. PubMed ID: 19145926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atrial fibrillation and heart failure: natural history and pharmacological treatment.
    Savelieva I; John Camm A
    Europace; 2004 Sep; 5 Suppl 1():S5-19. PubMed ID: 15450275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective ablation or isolation of all pulmonary veins in atrial fibrillation -- when and for whom?
    Walczak F; Szumowski L; Urbanek P; Szufladowicz E; Derejko P; Kułakowski P; Baranowski R; Bodalski R; Kepski R; Zagrodzka M; Onish K; Bestry I; Konka M; Kuśnierczyk B; Maryniak A
    Kardiol Pol; 2006 Jan; 64(1):26-35; discussion 36-7. PubMed ID: 16444625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-antiarrhythmic drugs in atrial fibrillation: a review of non-antiarrhythmic agents in prevention of atrial fibrillation.
    Lally JA; Gnall EM; Seltzer J; Kowey PR
    J Cardiovasc Electrophysiol; 2007 Nov; 18(11):1222-8. PubMed ID: 17553070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-ion channel blockers as anti-arrhythmic drugs (reversal of structural remodeling).
    Goette A; Bukowska A; Lendeckel U
    Curr Opin Pharmacol; 2007 Apr; 7(2):219-24. PubMed ID: 17276728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of atrial fibrillation and atrial flutter: Part II.
    Aronow WS
    Cardiol Rev; 2008; 16(5):230-9. PubMed ID: 18708824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outpatient use of anticoagulants, rate-controlling drugs, and antiarrhythmic drugs for atrial fibrillation.
    Allen LaPointe NM; Governale L; Watkins J; Mulgund J; Anstrom KJ
    Am Heart J; 2007 Nov; 154(5):893-8. PubMed ID: 17967595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. When should we discontinue antiarrhythmic therapy for atrial fibrillation after coronary artery bypass grafting? A prospective randomized study.
    Izhar U; Ad N; Rudis E; Milgalter E; Korach A; Viola N; Levi E; Asraff G; Merin G; Elami A
    J Thorac Cardiovasc Surg; 2005 Feb; 129(2):401-6. PubMed ID: 15678052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study.
    Sherman DG; Kim SG; Boop BS; Corley SD; Dimarco JP; Hart RG; Haywood LJ; Hoyte K; Kaufman ES; Kim MH; Nasco E; Waldo AL;
    Arch Intern Med; 2005 May; 165(10):1185-91. PubMed ID: 15911734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New antiarrhythmic agents for atrial fibrillation and atrial flutter.
    Pecini R; Elming H; Pedersen OD; Torp-Pedersen C
    Expert Opin Emerg Drugs; 2005 May; 10(2):311-22. PubMed ID: 15934869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.